Regeneron's experimental drug fianlimab, combined with its already-approved immunotherapy Libtayo (cemiplimab), failed to hit the primary endpoint in a Phase 3 clinical trial against Merck's Keytruda (pembrolizumab), according to Regeneron's announcement reported by CNBC and Stocktwits on May 15, 2026.

The goal was to prove the combination was statistically superior at improving progression-free survival (PFS) — how long patients with advanced melanoma live without their cancer getting worse.

The trial did not meet that goal.

The Numbers

Patients in the high-dose fianlimab arm lived a median of 11.5 months without their cancer worsening. Patients on Keytruda alone: 6.4 months.

That's a 5.1-month numerical difference. In advanced melanoma — a cancer that spreads fast and kills quickly — 5.1 months matters to a real patient.

But clinical trials don't run on gut feelings. They run on statistics. And that gap wasn't large enough, across enough patients, to clear the bar for statistical significance. By the rules of evidence-based medicine, Regeneron cannot claim the drug works better.

The lower-dose arm also fell short. No new safety concerns were reported, Regeneron said.

What Wall Street Said

The market reaction was swift and severe.

Shares fell 11.8% premarket Monday, according to CNBC. That's a brutal single-session hit for a company with serious market cap.

Evercore analyst Cory Kasimov called it bluntly: "These results are the worst-case scenario." He added that while the fundamental business impact is relatively limited right now, market sentiment will likely keep weakening.

For context on how Wall Street was positioned going in: according to Koyfin data cited by Stocktwits, 22 of 29 analysts covering Regeneron had a Buy or higher rating on the stock, with an average 12-month price target of $875.31 — about 25% above its last close before the trial news.

That's a lot of optimism now looking shaky.

What Comes Next

Regeneron has a second late-stage trial running — pitting the same fianlimab-Libtayo combination against Bristol Myers Squibb's Opdualag, according to Stocktwits. That trial is still live, with results pending.

This isn't a drug that got pulled. It's a drug that couldn't prove it was better than the best-in-class standard.

Beating Keytruda head-to-head is extraordinarily hard. Keytruda is the dominant force in cancer immunotherapy — a multi-billion-dollar blockbuster that has won its approvals across dozens of cancer types. Setting it as the comparator arm is a high bar by design.

Regeneron chose to swing for the fences. They didn't clear the statistical bar. But the second trial could still deliver results.

The Bigger Picture

Melanoma immunotherapy is one of the most competitive spaces in all of oncology. Merck's Keytruda and Bristol Myers Squibb's portfolio have dominated it for years. Every challenger faces the same brutal math: you have to be measurably, provably better — not just numerically better — to earn a new approval and carve out market share.

Regeneron was trying to do exactly that with fianlimab, a LAG-3 inhibitor designed to work alongside PD-1 blockade (Libtayo) to hit cancer cells through multiple immune pathways. The science makes sense. The trial just didn't generate the statistical proof needed.

Full results will be presented at a future medical conference, Regeneron said. That presentation may show subgroup data or secondary endpoints that provide additional context.

What This Means

For patients with advanced melanoma, nothing changes today. Keytruda remains the standard of care. The fianlimab combo remains investigational — no approved indication, as Stocktwits noted.

For Regeneron shareholders, the stock took a significant hit. Whether it's a buying opportunity or a warning sign depends heavily on what the second trial against Opdualag shows.

For the broader perspective: drug development is brutally hard, brutally expensive, and most trials fail. The real question is whether a 5.1-month difference in survival time should count as proof in clinical trials — and what standards we should demand.